RMD Quote, Financials, Valuation and Earnings

Becton, Dickinson & Co. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 8.37%. ResMed, Inc.'s return on equity of 25.6% beat Becton, Dickinson & Co.'s return on equity of 6.6%.

ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 20.04%. On the other hand Becton, Dickinson & Co. has an analysts' consensus of $204.83 which suggests that it could grow by 4.7%. Given that ResMed, Inc. has higher upside potential than Becton, Dickinson & Co., analysts believe ResMed, Inc. is more attractive than Becton, Dickinson & Co..

ResMed, Inc. has a beta of 0.866, which suggesting that the stock is 13.363% less volatile than S&P 500. In comparison Becton, Dickinson & Co. has a beta of 0.252, suggesting its less volatile than the S&P 500 by 74.828%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.93%. Becton, Dickinson & Co. offers a yield of 2.13% to investors and pays a quarterly dividend of $1.05 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Becton, Dickinson & Co. pays out 71.53% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Becton, Dickinson & Co. quarterly revenues of $5.9B. ResMed, Inc.'s net income of $348.5M is lower than Becton, Dickinson & Co.'s net income of $493M. Notably, ResMed, Inc.'s price-to-earnings ratio is 24.88x while Becton, Dickinson & Co.'s PE ratio is 33.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.80x versus 2.58x for Becton, Dickinson & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific Corp. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 14.91%. ResMed, Inc.'s return on equity of 25.6% beat Boston Scientific Corp.'s return on equity of 12.46%.

ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 20.04%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.86 which suggests that it could grow by 31.09%. Given that Boston Scientific Corp. has higher upside potential than ResMed, Inc., analysts believe Boston Scientific Corp. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.866, which suggesting that the stock is 13.363% less volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.673, suggesting its less volatile than the S&P 500 by 32.691%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.93%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend. ResMed, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. ResMed, Inc.'s net income of $348.5M is lower than Boston Scientific Corp.'s net income of $755M. Notably, ResMed, Inc.'s price-to-earnings ratio is 24.88x while Boston Scientific Corp.'s PE ratio is 51.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.80x versus 7.41x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 14.18%. ResMed, Inc.'s return on equity of 25.6% beat Stryker Corp.'s return on equity of 14.06%.

ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 20.04%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.9%. Given that Stryker Corp. has higher upside potential than ResMed, Inc., analysts believe Stryker Corp. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.866, which suggesting that the stock is 13.363% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.93%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.88 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. ResMed, Inc.'s net income of $348.5M is lower than Stryker Corp.'s net income of $859M. Notably, ResMed, Inc.'s price-to-earnings ratio is 24.88x while Stryker Corp.'s PE ratio is 46.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.80x versus 5.61x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 26.1% compared to ResMed, Inc.'s net margin of 17.41%. ResMed, Inc.'s return on equity of 25.6% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

ResMed, Inc. has a consensus price target of $291.80, signalling upside risk potential of 20.04%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 24.87%. Given that West Pharmaceutical Services, Inc. has higher upside potential than ResMed, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than ResMed, Inc..

ResMed, Inc. has a beta of 0.866, which suggesting that the stock is 13.363% less volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

ResMed, Inc. has a quarterly dividend of $0.60 per share corresponding to a yield of 0.93%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. ResMed, Inc. pays 22.3% of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed, Inc. quarterly revenues are $1.3B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. ResMed, Inc.'s net income of $348.5M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, ResMed, Inc.'s price-to-earnings ratio is 24.88x while West Pharmaceutical Services, Inc.'s PE ratio is 41.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed, Inc. is 6.80x versus 6.69x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.